

The British Journal of Diabetes & Vascular Disease

<http://dvd.sagepub.com/>

Overcoming the barriers to effective glycaemic control for type 2 diabetes

Charles A Reasner and Burkhard Göke

British Journal of Diabetes & Vascular Disease 2002 2: 290

DOI: 10.1177/14746514020020041001

The online version of this article can be found at:

<http://dvd.sagepub.com/content/2/4/290>

Published by:



<http://www.sagepublications.com>

Additional services and information for *The British Journal of Diabetes & Vascular Disease* can be found at:

Email Alerts: <http://dvd.sagepub.com/cgi/alerts>

Subscriptions: <http://dvd.sagepub.com/subscriptions>

Reprints: <http://www.sagepub.com/journalsReprints.nav>

Permissions: <http://www.sagepub.com/journalsPermissions.nav>

Citations: <http://dvd.sagepub.com/content/2/4/290.refs.html>

>> [Version of Record](#) - Jul 1, 2002

[What is This?](#)

Overcoming the barriers to effective glycaemic control for type 2 diabetes

CHARLES A REASNER,¹ BURKHARD GÖKE²

Introduction

The rising prevalence of type 2 diabetes will impose an increasing burden of diabetic complications on healthcare systems worldwide. The results of the UK Prospective Diabetes Study (UKPDS), and other studies, confirm the potential of effective glycaemic control to improve and extend the lives of people with type 2 diabetes. However, current management algorithms do not achieve sufficient glycaemic control in most patients to realise these improved clinical outcomes. We need a greater readiness to employ intensification of antidiabetic therapy earlier and in a manner that supports good compliance if we aim to maintain effective, long-term control of type 2 diabetes.

Audit of current diabetes management

Current management guidelines for type 2 diabetes in Europe and the USA set out challenging targets for glycaemic control.^{1,3} However, most type 2 diabetic patients managed in the community are not meeting these goals, and a survey of 6,544 patients in the UK (figure 1) suggests that during the 1990s only one in seven patients achieved $\text{HbA}_{1\text{C}} \leq 7.0\%$.⁴ Further evidence from Germany shows that in 1998 only 26% of patients achieved $\text{HbA}_{1\text{C}} < 6.5\%$.⁵ Data from the Third National Health and Nutrition Examination Survey (NHANES III) in the USA complement the European experience.⁶ The majority of patients with diabetes severe enough to receive pharmacological treatment had $\text{HbA}_{1\text{C}}$ above the US goal level of $\leq 7\%$, and a substantial minority (20–30%) had $\text{HbA}_{1\text{C}} > 9\%$ (figure 2).

We will face even greater challenges from type 2 diabetes in the future. The increasing obesity of the US population has driven a marked rise in the prevalence of type 2 diabetes. It is well known that obesity, particularly visceral adiposity, is associated with the development of insulin resistance and glucose intolerance.^{7,8} Between 1990 and 1998, the average weight of men and women in the USA increased by 3.4 kg and 3.9 kg, respec-

Figure 1. Patients achieving pre-defined treatment goals in a metropolitan area of the UK⁴





Figure 2. Mean $\text{HbA}_{1\text{C}}$ in cohorts of patients on different antidiabetic therapies in the USA (1988–1994): data from NHANES III⁶



¹ Texas Diabetes Institute and University of Texas Health Sciences Center, San Antonio, Texas, USA.

² Department of Internal Medicine II, Ludwig-Maximilians University of Munich, Germany.

Correspondence to: Dr Charles A Reasner

Texas Diabetes Institute, 701 S Zarzamora, San Antonio, Texas 78207-5209, USA.

Tel: +1 210 358 7402; Fax: +1 210 358 7406

E-mail: creasner@university-health-sys.com

Br J Diabetes Vasc Dis 2002;**2**:290–5

tively.⁹ During the same period, the prevalence of diabetes in the USA increased from 4.9% to 6.5%. The number of states with a prevalence of type 2 diabetes below 4% declined from seventeen to four, and the number of states with more than 6% of citizens with type 2 diabetes increased from two to twenty-five (figure 3).⁹

The global prevalence of type 2 diabetes is increasing and it is estimated that the number of people with diabetes will rise

Figure 3. Obesity and type 2 diabetes in the USA: a) mean body weight in American men and women; b) changing prevalences of type 2 diabetes⁹





Figure 4. Reduction in risk in diabetic complications associated with each 1% reduction in HbA_{1c} in the UKPDS¹⁶



from 150 million in the year 2000 to 220 million in 2010.¹⁰ Furthermore, half of all cases of type 2 diabetes are believed to be undiagnosed, and the insidious damage due to long-term hyperglycaemia is often evident even when patients present for diagnosis. Ultimately, some 60% of type 2 diabetic patients will die a cardiovascular death, with only one patient in five achieving a normal life span. The earlier diabetes is diagnosed, the more there is to lose: patients diagnosed in middle age (40–49 years) lose an estimated 7–10 years of life, compared with 5–7 years for patients diagnosed at age 50–59 years and 3–5 years for patients diagnosed at age 60–69 years.¹¹ This does not bode well for individuals diagnosed with type 2 diabetes at 20–30 years of age, who represent the fastest-growing segment of the type 2 diabetic population.

The cost of treating type 2 diabetes is high, especially man-

aging the complications which reduce both the quality and duration of life.^{12,13} More evidence from the CODE-2 study showed that, while diabetic patients without complications were 30% more expensive to manage compared with patients with other conditions, overall management costs for patients with both macrovascular and microvascular complications were more than four-fold greater than those for non-diabetic patients.⁵ Worldwide, the cost of managing diabetes alone accounts for as much as 2–3% of total healthcare expenditure in every country.¹⁴ The global pandemic of type 2 diabetes will represent the single greatest challenge to healthcare systems worldwide during the early decades of this century.

Importance of effective glycaemic control

The results of the UKPDS, among other studies, leave us in no doubt that effective control of glycaemia improves and extends the lives of patients with type 2 diabetes. The main analysis of the UKPDS determined the effects of intensive management on glycaemia and clinical outcomes. This was based on treatment with insulin or a sulphonylurea compared with a conventional management policy of diet and exercise in 3,867 patients followed for an average of ten years.¹⁵

An epidemiological analysis of the UKPDS revealed that a reduction in HbA_{1c} of 1% was associated with reductions in the risk of a range of diabetic complications (figure 4), including diabetes-related death (-21%), myocardial infarction (-14%), microvascular disease (-37%) and peripheral vascular disease (-43%).¹⁶

The association between HbA_{1c} and risk of complications was continuous and extended downwards into the normal range (HbA_{1c} < 6.0%). Thus, each 1% reduction in HbA_{1c} would be expected to deliver improvements in clinical outcomes.

Part of the UKPDS evaluated the effect of metformin, in comparison with diet-based treatment and intensive glycaemic

management with a sulphonylurea or insulin, in 1,704 overweight patients (defined as being > 120% of ideal body weight).¹⁷ Metformin significantly reduced the risk of any diabetes-related complication (by 32%), diabetes-related death (by 42%) and fatal or non-fatal myocardial infarction (by 39%), while trends towards reduced risk of stroke, peripheral vascular disease or microvascular complications did not achieve statistical significance.

The results of the UKPDS provide a strong base of evidence to underpin the benefits of effective glycaemic control. Identifying and overcoming the barriers to improving our management of type 2 diabetes will allow us to realise the benefits seen within the UKPDS for all of our type 2 diabetic patients.

Overcoming the barriers to effective control of diabetes

The dual metabolic defect of type 2 diabetes


Type 2 diabetes in almost all cases is driven by a dual metabolic defect of insulin resistance and a relative impairment of insulin secretion. Insulin resistance is usually well established by the time that diabetes is diagnosed, and remains at a relatively constant level throughout the remainder of the course of the disease.^{18,19} Although the impairment of beta-cell function also begins a number of years before the patient presents for diagnosis,²⁰ patients may still have sufficient beta-cell capacity to increase insulin secretion in an attempt to compensate for the insulin resistance for some years. As a result, a period of hyperinsulinaemia is often observed during the early years of clinical type 2 diabetes. Eventually, however, beta-cell function declines to the point where glycaemic control degenerates rapidly and treatment with exogenous insulin will be required.

Antidiabetic treatments may induce a short-term improvement in beta-cell function,²⁰ and some success has been achieved in delaying or preventing the onset of type 2 diabetes in glucose-intolerant individuals using lifestyle modification or metformin treatment.²¹ On the other hand, no treatment has yet been demonstrated to slow the decline in beta-cell function durably in patients with established type 2 diabetes. Thus, type 2 diabetes can be considered to represent a 'moving target',²² in that the underlying pathophysiology is dynamic in nature and unlikely to respond adequately to any single therapy during long-term treatment.

Limitations of diet/exercise and oral antidiabetic monotherapy

Current management algorithms for type 2 diabetes call for initial treatment with lifestyle modification followed by oral antidiabetic monotherapy. Therapy with diet and exercise controlled HbA_{1c} in only about one quarter of patients in the UKPDS after three years of treatment, and in less than 10% of patients after nine years of treatment (figure 5).²³ Data from the UKPDS have confirmed the limited efficacy of monotherapy in controlling glycaemia in the type 2 diabetic patient over the long term. Clearly, the majority of these patients would benefit from intensification of therapy using oral antidiabetic agents.

Figure 5. Patients in the UKPDS achieving HbA_{1c} < 7.0% on different treatment regimens²³




Even then, the dual metabolic defect underlying type 2 diabetes complicates the design of antidiabetic pharmacotherapy. Current oral antidiabetic monotherapy can address only one of the endocrine defects underlying the disease as its primary mechanism of action. Attempts to improve efficacy by increasing the dose of monotherapy may increase the likelihood of side effects²⁴ that often cause patients to discontinue treatment. For example, insulin secretagogues (sulphonylureas or meglitinides) are associated with hypoglycaemia or weight gain in some patients. The principal side effect of metformin is diarrhoea, though this can be minimised by careful titration of therapy. Metformin has also been associated with lactic acidosis, although the risk of this serious side effect is very low (three cases per 100,000 patient-years of treatment).²⁵ Thiazolidinediones cause weight gain, along with oedema in some patients, and have a limited indication in Europe. Finally, α -glucosidase inhibitors induce frequent and troublesome gastrointestinal side effects and the need for frequent daily dosing may hinder compliance (see below).

For these reasons, long-term antidiabetic monotherapy will be sufficiently effective for only a minority of patients. For example, in the UKPDS, therapy with a sulphonylurea, metformin or insulin controlled HbA_{1c} to below 7% in less than half of the patient population after three years of treatment, and in only about one quarter of patients or less after nine years of treatment (figure 5).²³ These data emphasise the need to challenge the way that we manage type 2 diabetes, starting from the early stages of the disease, in order to maintain protection from diabetic complications from the point of diagnosis.

Moving away from failure-based glycaemic management

The progressive nature of type 2 diabetes requires regular adjustment of therapy to retain metabolic control. All too often, however, management strategies for type 2 diabetes are 'failure-based', in that there is a tendency to persist with monotherapy

Figure 6. Levels of glycaemia at which US physicians stated their intention to apply intensified antidiabetic therapies




until glycaemic control has been lost, perhaps irretrievably. The maximum efficacy of an oral antidiabetic treatment is achieved within 2–3 months,^{26,27} so that intensification of therapy will be required if glycaemic control is not achieved. Furthermore, increasing the dose of an insulinotropic agent beyond half of the maximally recommended dosage usually produces little additional efficacy.^{27–29}

An early switch to antidiabetic combination treatment that addresses the dual endocrine defects of insulin resistance and beta-cell dysfunction, would deliver a markedly greater reduction in HbA_{1c} for such patients and would provide a prompt and clinically important reduction in the risk of diabetic complications, as described above.¹⁶ Furthermore, there is evidence that physicians may tolerate higher levels of hyperglycaemia in patients who receive more complex antidiabetic regimens, compared with those receiving diet and exercise or oral antidiabetic monotherapy. A survey of primary care physicians in the USA found that, on average, diet and exercise therapy would commence when fasting plasma glucose (FPG) reached 7.4 mmol/L (134 mg/dL) (figure 6). The same survey showed that patients would not receive an oral antidiabetic combination, or oral therapy plus insulin, until further marked deteriorations in glycaemia had been observed (figure 6). These data imply that patients requiring more intensive therapy are being exposed unnecessarily to hyperglycaemia.

A new approach to diabetes management is needed which recognises the urgent need to control glycaemia as a central part of the therapeutic strategy. This requires a greater readiness on the part of physicians to intensify antidiabetic therapy earlier and more frequently, using rational combinations of antidiabetic treatments with complementary mechanisms of action. For example, the combination of metformin, which addresses insulin resistance as its primary mechanism, with an insulinotropic agent such as a sulphonylurea or meglitinide, which enhance beta-cell function, addresses both components of the dual endocrine defects of type 2 diabetes.

Well-designed clinical studies support the use of such combinations to deliver better glycaemic control than oral monotherapy in patients previously treated with diet^{27,30} or oral antidiabetic monotherapy.^{31–35} Figure 7 shows improved efficacy with met-

Figure 7. Glucose-lowering efficacy of single-tablet combination therapy compared with monotherapies in patients previously treated with diet and exercise,³⁰ at least half-maximal doses of a sulphonylurea³⁵ or metformin³⁴




formin and glibenclamide (glyburide in the USA), as a single tablet (Glucovance®), compared with either agent given as monotherapy in patients previously treated with diet, metformin or a sulphonylurea. The incidence of hypoglycaemic symptoms with the lower dosage strength of the single combination tablet (which could be used to initiate combination therapy) was either lower than³⁰ or similar to glibenclamide alone.^{34,35} While there is clinical evidence supporting the use of metformin and a sulphonylurea in combination, combinations of other oral antidiabetic agents may also be of benefit.

The use of such single-tablet combinations differs from the conventional use of free combinations. With a free combination, the first component is usually titrated to the maximum efficacy, tolerability or permitted dose. The second component is then added at a low dose and the titration process repeated. With a single-tablet combination, treatment can commence with both components at a relatively low dose and then titrated in parallel. This approach uses potential synergy between the components to enhance glucose-lowering efficacy with relatively low doses of both components.

Poor compliance with therapy

Type 2 diabetic patients bear a burden of polypharmacy³⁶ which is a barrier to compliance.^{37,38} Indeed, many patients need to take as many as ten different medications every day for their diabetes and concurrent conditions. Given the need to take different medications, with different dosage frequencies and different numbers of tablets at different times of the day, it is hardly surprising that many patients are unable to follow treatment regimens closely. The Diabetes Audit and Research in Tayside, Scotland (DARTS) study provides a quantitative evaluation of the impact of regimen complexity on compliance with antidiabetic therapy.^{39,40} The medication details of 2,920 patients were

Figure 8. Impact of polypharmacy on adherence to an antidiabetic regimen in the DARTS study³⁹



followed retrospectively for 12 months, and information on prescriptions issued were used in the calculation of an 'Adherence Index', an estimate of the extent of actual therapeutic coverage from the antidiabetic treatment. Patients with an Adherence Index > 90% were considered to have complied adequately with therapy.

Only about 30% of patients met this goal while receiving monotherapy with either a sulphonylurea or metformin but adherence to therapy worsened by 13% when a free combination of these agents was used (figure 8). Furthermore, annual drug coverage was greater ($p < 0.01$) in patients receiving monotherapy with a sulphonylurea (300 days) or metformin (302 days) than in patients receiving a free combination of these antidiabetic agents (266 days).

The DARTS study confirms the adverse impact of complex treatment regimens on routine adherence to therapy. Even the most effective treatment cannot benefit patients if it is not taken as prescribed. It is important that intensification of treatment regimens do not reduce patient compliance. The use of novel formulations, including single-tablet combinations, provides an avenue for further evaluation.

Looking ahead

The challenging glycaemic targets in current management guidelines provide a useful framework for improving patient outcomes in type 2 diabetes. We know that intensive oral antidiabetic regimens are effective, and reduce the risk of diabetic complications^{15,17} without impairing patients' quality of life.⁴¹ A greater readiness to treat to target and to intensify therapy earlier will form a key element in future diabetes management strategies. Single-tablet combinations offer the potential to maximise antidiabetic efficacy without reducing patient compliance and single-tablet combinations are already accepted in other fields of medicine.^{42,43}

Current treatment algorithms need updating to include the use of single-tablet combinations in the management of type 2 diabetes. Indeed, a recent review of target-driven care conclud-



Key messages

- Effective glycaemic control improves and extends the lives of people with type 2 diabetes
- Poor glycaemic control remains widespread in community practice
- We need to overcome barriers to effective glycaemic control
- Earlier use of combination therapy, in a manner that supports patient compliance, is required

ed that the development of single-tablet combination therapies 'seems of the utmost priority for the prevention of complications of type 2 diabetes'.⁴⁴

References

1. European Diabetes Policy Group. A desktop guide to type 2 diabetes mellitus. *Diabet Med* 1999;**16**:716-30.
2. American Diabetes Association: clinical practice recommendations. *Diabetes Care* 1999;**22**(suppl 1):S1-114.
3. American Association of Clinical Endocrinologists. Medical guidelines for the management of diabetes mellitus: The AACE system of intensive diabetes self-management – 2002 Update. *Endocrine Practice* 2002;**8**(suppl 1):40-82.
4. New JP, Hollis S, Campbell F *et al*. Measuring clinical performance and outcomes from diabetes information systems: an observational study. *Diabetologia* 2000;**43**:836-43.
5. Liebl A, Neiss A, Spannheimer A, Reitberger U, Wagner T, Gortz A. Costs of type 2 diabetes in Germany. Results of the CODE-2 study. *Dtsch Med Wochenschr* 2001;**126**:585-9.
6. Harris MI, Eastman RC, Cowie CC, Flegal KM, Eberhardt MS. Racial and ethnic differences in glycemic control of adults with type 2 diabetes. *Diabetes Care* 1999;**22**:403-08.
7. Banerji MA, Buckley MC, Chaiken RL, Gordon D, Lebovitz HE, Kral JG. Liver fat, serum triglycerides and visceral adipose tissue in insulin-sensitive and insulin-resistant black men with NIDDM. *Int J Obes Relat Metab Disord* 1995;**19**:846-50.
8. Banerji MA, Faridi N, Atluri R, Chaiken RL, Lebovitz HE. Body composition, visceral fat, leptin, and insulin resistance in Asian Indian men. *J Clin Endocrinol Metab* 1999;**84**:137-44.
9. Mokdad AS, Ford EH, Bowman BA *et al*. Diabetes trends in the US: 1990–1998. *Diabetes Care* 2000;**23**:1278–83.
10. Day C. The rising tide of type 2 diabetes. *Br J Diabetes Vasc Dis* 2001;**1**:37-43.
11. Panzram G. Mortality and survival in type 2 (non-insulin-dependent) diabetes mellitus. *Diabetologia* 1987;**30**:123-31.
12. Gray A, Raikou M, McGuire A *et al*. Cost effectiveness of an intensive blood glucose control policy in patients with type 2 diabetes: economic analysis alongside randomised controlled trial (UKPDS 41). *BMJ* 2000;**320**:1373-8.
13. Caro JJ, Ward AJ, O'Brien JA. Lifetime costs of complications resulting from type 2 diabetes in the US. *Diabetes Care* 2002;**25**:476-81.
14. Jönsson B. The economic impact of diabetes. *Diabetes Care* 1998;**21**(suppl 3):C7-10.
15. UK Prospective Diabetes Study Group. Intensive blood glucose control with sulphonylurea or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). *Lancet* 1998;**352**:837-53.

16. Stratton MI, Adler AI, Neil AW *et al.* Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): prospective observational study. *BMJ* 2000;**321**:405-12.
17. UK Prospective Diabetes Study (UKPDS) Group. Effect of intensive blood glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). *Lancet* 1998;**352**:854-65.
18. DeFronzo RA, Bonnadonna RC, Ferrannini E. Pathogenesis of NIDDM. A balanced overview. *Diabetes Care* 1992;**15**:318-68.
19. DeFronzo RA. Insulin resistance: a multifaceted syndrome responsible for NIDDM, obesity, hypertension, dyslipidaemia and atherosclerosis. *Neth J Med* 1997;**50**:191-7.
20. UK Prospective Diabetes Study Group. UK prospective diabetes study 16. Overview of 6 years' therapy of type II diabetes: a progressive disease. UK Prospective Diabetes Study Group. *Diabetes* 1995;**44**:1249-58.
21. Diabetes Prevention Program Research Group. Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. *N Engl J Med* 2002;**346**:393-403.
22. Bailey CJ. Diabetes control: Treating a moving target. *Internal Med* 1996;**17**:90-101.
23. Turner RC, Cull CA, Frighi V, Holman RR. Glycaemic control with diet, sulphonylurea, metformin or insulin in patients with type 2 diabetes mellitus: Progressive requirement for multiple therapies (UKPDS 49). *JAMA* 1999;**281**:2005-12.
24. Krentz AJ, Ferner RE, Bailey CJ. Comparative tolerability profiles of oral antidiabetic agents. *Drug Saf* 1994;**11**:223-41.
25. Howlett HC, Bailey CJ. A risk-benefit assessment of metformin in type 2 diabetes mellitus. *Drug Saf* 1999;**20**:489-503.
26. Haupt E, Knick B, Koschinsky T *et al.* Oral antidiabetic combination therapy with sulphonylureas and metformin. *Diabet Metab* 1991;**27**:224-31.
27. Hermann LS, Schersten B, Melander A. Antihyperglycaemic efficacy, response prediction and dose-response relations of treatment with metformin and sulphonylurea, alone and in primary combination. *Diabet Med* 1994;**11**:953-60.
28. Gribble FM, Manley SE, Levy JC. Randomized dose ranging study of the reduction of fasting and postprandial glucose in type 2 diabetes by nateglinide (A-4166). *Diabetes Care* 2001;**24**:1221-25.
29. Goldberg RB, Holvey SM, Schneider J. A dose-response study of glimepiride in patients with NIDDM who have previously received sulphonylurea agents. The Glimepiride Protocol #201 Study Group. *Diabetes Care* 1996;**19**:849-56.
30. Garber AJ, Larsen J, Schneider SH, Piper BA, Henry D. Simultaneous glyburide/metformin monotherapy is superior to component monotherapy as initial pharmacological treatment for type 2 diabetes. *Diab Obes Metab* 2002;**4**:201-08.
31. Moses R, Carter J, Slobodniuk R *et al.* Effect of repaglinide addition to metformin monotherapy on glycemic control in patients with type 2 diabetes. *Diabetes Care* 1999;**22**:119-24.
32. DeFronzo RA, Goodman AM. Efficacy of metformin in patients with non-insulin dependent diabetes mellitus. *N Engl J Med* 1995;**333**:541-9.
33. Charpentier G, Fleury F, Kabir M *et al.* Improved glycaemic control by addition of glimepiride to metformin monotherapy in type 2 diabetic patients. *Diabet Med* 2001;**16**:828-34.
34. Marre M, Howlett H, Lehert P, Allavoine T. Improved glycaemic control with metformin-glibenclamide combined tablet therapy (Glucovance®) in type 2 diabetic patients inadequately controlled on metformin. *Diabet Med* 2002;**19**:673-80.
35. Blonde L, Rosenstock J, Mooradian AD, Piper BA, Henry D. Glyburide/metformin combination product is safe and efficacious in patients with type 2 diabetes failing sulphonylurea therapy. *Diabetes Obes Metab* (in press).
36. Veehof L, Stewart R, Haaijer-Ruskamp F, Jong BM. The development of polypharmacy. A longitudinal study. *Fam Pract* 2000;**17**:261-7.
37. Paes AHP, Bakker A, Soe-Agnie S-J. Impact of dosage frequency on patient compliance. *Diabetes Care* 1997;**20**:1512-17.
38. Brown JB, Nichols GA, Glauber HS, Bakst A. Ten-year follow-up of antidiabetic drug use, nonadherence, and mortality in a defined population with type 2 diabetes mellitus. *Clin Ther* 1999;**21**:1045-57.
39. Morris AD, Brennan GM, Macdonald TM, Donnan PT. Population-Based Adherence to Prescribed Medication in Type 2 Diabetes: A Cause for Concern. *Diabetes* 2000;**49**(suppl 1):A76.
40. Donnan PT, MacDonald TM, Morris AD. Adherence to prescribed oral hypoglycaemic medication in a population of patients with type 2 diabetes: a retrospective cohort study. *Diabet Med* 2002;**19**:279-84.
41. UK Prospective Diabetes Study (UKPDS) Group. Quality of life in type 2 diabetic patients is affected by complications but not by policies to improve blood glucose or blood pressure control. *Diabetes Care* 1999;**22**:1125-36.
42. Guidelines Subcommittee. 1999 World Health Organisation – International Society of Hypertension. Guidelines for the Management of Hypertension. *J Hypertens* 1999;**17**:151-83.
43. Joint National Committee. Sixth National Report of the Joint National Committee on Prevention, Detection, Evaluation and Treatment of High Blood Pressure (JNC VI). *Arch Intern Med* 1997;**157**:2413-46.
44. Winocour PH. Effective diabetes care: a need for realistic targets. *BMJ* 2002;**324**:1577-80.